The positive RAD 101 Phase 2b data and planned Phase 3 initiation are significant catalysts, but the dilutive capital raise and rapid cash burn ($14.97M/quarter) create near-term financing risk. Monitor for Phase 3 enrollment updates and potential additional capital needs. The stock may react positively to the clinical milestone but face headwinds from dilution.
Price Chart
Executive Summary
Radiopharm Theranostics reported positive Phase 2b results for RAD 101 (93% primary endpoint achievement) and plans a Phase 3 registrational trial in Q4 2026. The company raised ~$12.5M via an institutional offer and launched a $6M Share Purchase Plan post-quarter, with cash burn of $14.97M in the quarter. The pre-revenue biotech's financial results are nominal (no revenue), making the clinical catalyst the primary driver, but the dilutive capital raise and high cash burn temper the outlook.
Key Facts
- Phase 2b trial of RAD 101 met primary endpoint with 93% of evaluable patients achieving concordance with MRI imaging.
- Company plans to initiate Phase 3 registrational trial of RAD 101 in Q4 2026.
- Post-quarter, raised ~$12.5M via institutional offer and launched a $6M Share Purchase Plan (already subscribed for up to $3M).
- Closing cash at end of quarter was $4.1M, down from $19.2M in prior quarter.
- Net cash outflows from operating activities were $14.97M, with R&D and staff costs accounting for 95%.
- Received FY25 Australian R&D Tax Incentive of $5.9M post-quarter.
- RAD 204 Phase 1 data showed first patient in third cohort achieved RECIST-confirmed partial response with -43% tumor shrinkage.
- No revenue reported; company is pre-revenue clinical-stage biotech.
Financial Impact
No revenue; cash burn of $14.97M in the quarter; post-quarter capital raises total ~$12.5M institutional + up to $6M SPP; cash position $4.1M at quarter end.
Risk Factors
- Dilution from institutional offering and Share Purchase Plan (combined up to ~$18.5M) against a ~$41M market cap.
- Cash burn rate of ~$15M/quarter with only $4.1M cash at quarter end, requiring further capital raises.
- Pre-revenue stage with no approved products; clinical trial risk for Phase 3 RAD 101.
- OTC listing with low liquidity and small market cap increases volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9960 (+0.61%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9960 (−7.78%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9960 (−21.57%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9960 (−32.70%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9960 (−38.52%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9960 (+36.64%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9960 (−39.64%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9960 (−50.45%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9960 (−49.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers